Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

BelgiumBack to Belgium

Clinical trials in Mechelen – page 121

1 898 clinical trials in Mechelen, Belgium across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

Mechelen at a glance
1 898
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

1 898 trials in Mechelen

Open in trial search

Colorectal cancer metastatic

Not recruiting

Study Comparing Nivolumab, Nivolumab with Ipilimumab, or Chemotherapy for Patients with Metastatic Colorectal Cancer with High Microsatellite Instability

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Bladder transitional cell carcinoma

Not recruiting

Study on TAR-200 and Cetrelimab for Patients with High-Risk Non-Muscle Invasive Bladder Cancer Who Have Not Received BCG Treatment

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Cetrelimab
  • Sponsor:Janssen Cilag International

Non-small cell lung cancer+1

Not recruiting

Study Comparing Pralsetinib and Standard Drug Combination for Patients with Advanced RET Fusion-Positive Non-Small Cell Lung Cancer

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:F. Hoffmann-La Roche AG

Oesophageal squamous cell carcinoma

Not recruiting

Study of Durvalumab with Chemoradiation Therapy for Patients with Locally Advanced, Unresectable Esophageal Squamous Cell Carcinoma

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Capecitabine
  • Sponsor:AstraZeneca AB

Respiratory tract infection

Not recruiting

Study on Nitric Oxide and Saline Nasal Sprays for Treating COVID-19 and Similar Illnesses in Primary Care Patients

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Nitric Oxide
  • Sponsor:Universitair Medisch Centrum Utrecht

Follicle centre lymphoma follicular grade I II - III refractory

Not recruiting

Study on the Safety and Effectiveness of Epcoritamab with Rituximab and Lenalidomide for Patients with Relapsed or Refractory Follicular Lymphoma

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Epcoritamab
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Diffuse large B-cell lymphoma

Not recruiting

Study on the Safety and Effectiveness of Epcoritamab with R-CHOP for Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Cyclophosphamide
  • Sponsor:AbbVie Deutschland GmbH & Co. KG

Transitional cell carcinoma

Not recruiting

Study Comparing Erdafitinib with Vinflunine, Docetaxel, or Pembrolizumab for Patients with Advanced Urothelial Cancer and FGFR Gene Changes

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Docetaxel
  • Sponsor:Janssen Cilag International

Amyotrophic lateral sclerosis

Not recruiting

Study of utreloxastat (PTC857) in adults with Amyotrophic Lateral Sclerosis (ALS) to evaluate its effectiveness in slowing disease progression

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Sponsor:PTC Therapeutics Inc.

Cholangiocarcinoma

Not recruiting

Study of Tucatinib and Trastuzumab for Patients with Advanced Solid Tumors with HER2 Changes

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Fulvestrant
  • Sponsor:Seagen Inc.

Colitis ulcerative+2

Not recruiting

Study on Subcutaneous Infliximab for Patients with Ulcerative Colitis, Crohn's Disease, or Unclassified Inflammatory Bowel Disease

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Infliximab
  • Sponsor:Belgian IBD Research and Development

Prostate cancer

Not recruiting

Study of Stereotactic Body Radiotherapy with or without Darolutamide for Patients with Oligorecurrent Prostate Cancer

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Darolutamide
  • Sponsor:Universitair Ziekenhuis Gent

Other cities in Belgium

The busiest research cities in the country

All 164 cities in Belgium

Clinical research in Mechelen

What the registry says about research in the country

01 Respiratory Health Research

Current studies focus on respiratory infections and preventive measures, including innovative vaccine trials for RSV and influenza in various age groups. Research encompasses both standalone treatments and combination therapies.

  • RSV Vaccine Development
  • Influenza Prevention
  • COVID-19 Co-administration Studies

Special attention is given to protecting vulnerable populations, particularly adults over 60 years of age.

02 Oncology Studies

Groundbreaking research in lung cancer treatment, particularly focusing on non-small cell and small cell variants. Studies evaluate novel therapeutic approaches including immunotherapy combinations.

  • NSCLC Treatment Innovations
  • Lymphoma Therapies
  • Targeted Drug Development

Investigations include both first-line treatments and advanced therapy options.

03 Cardiovascular and Metabolic Research

Studies addressing cardiovascular disease and related conditions, including trials for hypertriglyceridemia and stroke prevention in atrial fibrillation patients.

  • Lipid Management
  • Stroke Prevention
  • Cardiovascular Risk Reduction

Focus on both preventive measures and treatment of existing conditions.

Back to BelgiumAll countries
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.